A heterologous vaccine regimen consisting of a first dose of the AstraZeneca vaccine and a second dose of the Pfizer vaccine induces a stronger immune response than a regimen consisting of two doses of the AstraZeneca vaccine.
The emergence and spread throughout Europe of a SARS-CoV-2 variant, 20E (EU1) in the summer of 2020 illustrates how a virus may become dominant not by increased transmissibility but through travel and lack of effective containment and screening. The SARS-CoV-2 variant 20E (EU1) emerged in Spain in the summer of 2020 and spread to multiple …
Holiday travel explains spread of a SARS-CoV-2 variant Read More »
Early in the COVID-19 pandemic, SARS-CoV-2 genome variation appeared to be low, with an average of 10 base differences in the 30,000 base genome between any two isolates. Late in 2020, as many more people were infected, variants were isolated that had more changes than previously seen. A study of variation at the genome level …
SARS-CoV-2 variants arise during individual infections Read More »
